REFERENCES
- Holt SG, Moore KP. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med. 2001;27:803–811.
- Holt S, Moore K. Pathogenesis of renal failure in rhabdomyolysis: The role of myoglobin. Exp Nephrol. 2000;8:72–76.
- Falagas ME, Kasiakou SK. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care. 2006;10:27.
- Wareham DW, Bean DC, Khanna P, . Bloodstream infection due to Acinetobacter spp.: Epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008;27:607–612.
- Berg JR, Spilker CM, Lewis SA. Modulation of polymyxin B effects on mammalian urinary bladder. Am J Physiol. 1998;275:204–215.
- Evagelopoulou P, Katsaros A, Myrianthefs P, . Colistin and rhabdomyolysis: A causative agent or an innocent bystander? Intensive Care Med. 2007;33:556–557.
- Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: Historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010;48:749–756.
- Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents. 2009;34:434–438.
- Moore KP, Holt SG, Patel RP, . A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failure. J Biol Chem. 1998;273: 31731–31737.